Abstract:Corrigendum: Oncolytic Adenovirus—A Nova for Gene-Targeted Oncolytic Viral Therapy in HCCMubalake Abudoureyimu1, Yongting Lai2, Chuan Tian1, Ting Wang3, Rui Wang1* and Xiaoyuan Chu11 Department of Medical Oncology, Jinling Hospital, School of Medicine, Nanjing University, Nanjing, China2 Department of Medical Oncology, Jinling Hospital, Nanjing Clinical School of Southern Medical University, Nanjing, China3 Department of Medical Oncology, Jinling Hospital, Nanjing, China* Correspondence: Rui Wang, wangrui218@163.comKeywords: gene-targeted oncolytic viral therapy, adenovirus, HCC, immunotherapy, virus engineeringCorrigendum on: Abudoureyimu M, Lai Y, Tian C, Wang T, Wang R and Chu X (2019) Oncolytic Adenovirus—A Nova for Gene-Targeted Oncolytic Viral Therapy in HCC. Front. Oncol. 9:1182. doi: 10.3389/fonc.2019.01182 Missing FundingIn the original article, we neglected to include the funder **the Excellent Youth Foundation of Jiangsu Province, China**, **BK20140032** to **Rui Wang**. The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Corrigendum: Innovative retargeted oncolytic herpesvirus against nectin4-positive cancers

Corrigendum: CAR T Cells Targeting the Tumor MUC1 Glycoprotein Reduce Triple-Negative Breast Cancer Growth

Corrigendum: Oncolytic Adenovirus—A Nova for Gene-Targeted Oncolytic Viral Therapy in HCC

Corrigendum: Myelomodulatory treatments augment the therapeutic benefit of oncolytic viroimmunotherapy in murine models of malignant peripheral nerve sheath tumors

Corrigendum: Targeting HER3 to overcome RGFR TKI resistance in NSCLC

Correction to: The limiting factors of oncolytic virus immunotherapy and the approaches to overcome them

Corrigendum: Dual-Targeting Nanoparticle-Mediated Gene Therapy Strategy for Hepatocellular Carcinoma by Delivering Small Interfering RNA

Corrigendum to “A tumor cell membrane-coated self-amplified nanosystem as a nanovaccine to boost the therapeutic effect of anti-PD-L1 antibody” [Bioact. Mater. 21 299–312]

Corrigendum to "A Novel Inhibitor of MDM2 Oncogene Blocks Metastasis of Hepatocellular Carcinoma and Overcomes Chemoresistance" [genes Dis 694 (2019) 419-430].

Corrigendum: Ex vivo modulation of intact tumor fragments with anti-PD-1 and anti-CTLA-4 influences the expansion and specificity of tumor-infiltrating lymphocytes

Corrigendum: HSA-nanobinders crafted from bioresponsive prodrugs for combined cancer chemoimmunotherapy-an in vitro exploration

Erratum: Targeting Telomere Dynamics as an Effective Approach for the Development of Cancer Therapeutics [Corrigendum]

Erratum: Efficacy and safety evaluations of anlotinib in patients with advanced non-small cell lung cancer treated with bevacizumab

Corrigendum: NDRG1 Inhibition Sensitizes Osteosarcoma Cells to Combretastatin A-4 Through Targeting Autophagy

Corrigendum: Circulating cell-free DNA and IL-10 from cerebrospinal fluids aid primary vitreoretinal lymphoma diagnosis

Corrigendum: Targeting Myc Interacting Proteins As a Winding Path in Cancer Therapy

Corrigendum: Anlotinib Combined With Anti-PD-1 Antibodies Therapy in Patients With Advanced Refractory Solid Tumors: A Single-Center, Observational, Prospective Study

Erratum: Effects of HPV16E6 transfection on the biological behavior of Eca109 and Eca9706 cells

Correction: Gravina et al. ATX-101, a Peptide Targeting PCNA, Has Antitumor Efficacy Alone or in Combination with Radiotherapy in Murine Models of Human Glioblastoma. Cancers 2022, 14, 289

Correction to “Targeting the Spike: Repurposing Mithramycin and Dihydroergotamine to Block SARS-CoV-2 Infection”

[Corrigendum] miR‐146b‐5p inhibits tumorigenesis and metastasis of gallbladder cancer by targeting Toll‐like receptor 4 via the nuclear factor‐κB pathway